ABIVAX Société Anonyme (NASDAQ:ABVX) Short Interest Update

ABIVAX Société Anonyme (NASDAQ:ABVX) was the target of a significant decrease in short interest in the month of October. As of October 15th, there was short interest totalling 227,200 shares, a decrease of 16.5% from the September 30th total of 272,200 shares. Approximately 0.4% of the shares of the company are sold short. Based on an average trading volume of 118,000 shares, the days-to-cover ratio is presently 1.9 days.

Analyst Ratings Changes

Separately, Laidlaw started coverage on shares of ABIVAX Société Anonyme in a report on Monday, July 29th. They issued a “buy” rating and a $48.00 target price on the stock. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $36.50.

ABIVAX Société Anonyme Stock Performance

Shares of ABIVAX Société Anonyme stock opened at $10.30 on Monday. ABIVAX Société Anonyme has a one year low of $8.75 and a one year high of $17.02. The firm has a fifty day moving average of $11.09 and a two-hundred day moving average of $12.63.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets purchased a new stake in ABIVAX Société Anonyme in the 1st quarter valued at approximately $81,000. Capstone Investment Advisors LLC lifted its holdings in shares of ABIVAX Société Anonyme by 9.0% in the 1st quarter. Capstone Investment Advisors LLC now owns 62,966 shares of the company’s stock valued at $900,000 after buying an additional 5,199 shares during the period. Kennedy Capital Management LLC boosted its stake in shares of ABIVAX Société Anonyme by 35.3% in the first quarter. Kennedy Capital Management LLC now owns 120,168 shares of the company’s stock valued at $1,718,000 after buying an additional 31,331 shares in the last quarter. abrdn plc grew its holdings in ABIVAX Société Anonyme by 167.7% during the third quarter. abrdn plc now owns 316,431 shares of the company’s stock worth $3,645,000 after acquiring an additional 198,225 shares during the period. Finally, Janus Henderson Group PLC raised its position in ABIVAX Société Anonyme by 18.2% in the first quarter. Janus Henderson Group PLC now owns 851,839 shares of the company’s stock worth $12,113,000 after acquiring an additional 131,414 shares in the last quarter. 47.91% of the stock is owned by hedge funds and other institutional investors.

ABIVAX Société Anonyme Company Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.